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Linezolid for drug-susceptible tuberculosis 
We question why linezolid would be included in a regimen for drug-susceptible tuberculosis (DS-TB) 
as described by Jung Kyu Lee et al1 given its known toxicity profile. Regardless of the underlying 
premise, we have significant concerns about the manner in which the data have been analysed, 
presented, and the conclusions that have been drawn. 
It is unclear why certain patients were excluded from the modified intention to treat (mITT) analysis. 
For example, those who did not take adequate trial medication should have been included in the 
mITT population.  
Although participants were enrolled on the basis of being Xpert positive, only 285 (74%) were 
subsequently found to be culture positive at baseline. Therefore, the mITT population includes 
participants who were culture negative at enrolment and consequently could not contribute to the 
primary outcome of culture conversion. Therefore, the numbers at risk in Figure 2 are clearly 
incorrect. 
Too much weight is given in the paper the per-protocol (PP) analysis, a biased assessment not 
appropriate in a trial with a superiority hypothesis.  This overemphasis has influenced the authors’ 
conclusions that there is a potential role for linezolid in treating DS-TB as they have focused on an 
analysis that does not properly reflect the treatment effect of the regimen.   
Selecting regimens to take forward into treatment shortening trials is a complex decision. For the 
reasons we outline above, we do not think the authors' conclusions are supported by the data. The 
capacity to undertake randomised controlled trials in tuberculosis is currently severely limited, 
therefore it is critical that these trials are properly designed, analysed and reported.  
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